CALGARY — Paralyzed Humboldt Broncos player Ryan Straschnitzki is on his hands and knees trying a skill he hasn‘t had to practise for 18 years — how to crawl.
Straschnitzki, with the assistance of two physiotherapists, is being shown how to keep himself upright on his arms and how to move his legs forward, a few inches at a time.
First-in-human clinical study found improved motor and sensory function in three of four participants
Writing in the June 1 issue of Cell Stem Cell, researchers at University of California San Diego School of Medicine report that a first-in-human phase I clinical trial in which neural stem cells were transplanted into participants with chronic spinal cord injuries produced measurable improvement in three of four subjects, with no serious adverse effects.
An investigational scaffold device from InVivo Therapeutics increases the likelihood that a patient with acute thoracic complete spinal cord injury will have a neurologic status ‘conversion’ from complete paraplegia to incomplete injury, according to findings presented at the American Association of Neurological Surgeons 2018 Annual Meeting in New Orleans and detailed in Medscape.
Here are four things to know.
When Paul Burnett first met Kamden Houshan in kindergarten, the two boys quickly became friends. They bonded over playing superheroes and creating goofy videos. While others often focus on Kamden’s wheelchair and disability, Paul never acted like Kamden was different.
“What really contributes to their friendship is that Paul does not see Kamden as someone who has a disability. He sees him as Kamden. Because of that Kam truly is himself around him,” Yvonne Houshan, Kamden’s mom, told TODAY.
I am Tamara Mena and I am 30 years old. I’m a host, model, and motivational speaker.
First robotic exoskeleton cleared for use with stroke and spinal cord injury levels to C7
RICHMOND, Calif., April 04, 2016 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Ekso GT robotic exoskeleton for use in the treatment of individuals with hemiplegia due to stroke, individuals with spinal cord injuries at levels T4 to L5, and individuals with spinal cord injuries at levels of T3 to C7 (ASIA D), in accordance with device’s labeling. The Ekso GT is the first exoskeleton cleared by the FDA for use with stroke patients.
Denny Ross – paralyzed from the chest down in a car accident – has gone from counting his steps to counting kilometres, attempting to finish a five kilometre race with the use of a ReWalk exoskeleton on Saturday.
“It’s a huge step,” he said with a laugh while taking part in the N.E.R.D. Run at William Hawrelak Park, an annual fundraiser supporting the University of Alberta’s Neuroscience and Mental Health Institute.
Ross has been using the exoskeleton as part of a pilot study examining the effects of using the ReWalk device, purchased by the Spinal Cord Injury Treatment Society in 2014 and leased to the university for the trial.